Orchestrating cell cycle arrest and innate immune sensing for synergistic radiotherapy and immunotherapy against non-small cell lung cancer

Authors: You, Lukuan; Chen, Zhuang; Bei, Jiayi; Cui, Can; Xu, Yinmei; Fu, Yankan; Ren, Yifan; Chen, Bo; Wang, Zhongliang; Li, Jianxiong

Source journal: Journal of nanobiotechnology (2026-08-26)

DOI: 10.1186/s12951-026-04980-4

Abstract

Radiotherapy combined with immunotherapy is a pivotal strategy for non-small cell lung cancer; yet, its efficacy is severely compromised by tumor heterogeneity and insufficient innate immune activation. Herein, a tumor microenvironment responsive GSK@BSA-MnO(2) nanoplatform is engineered to spatiotemporally synchronize cell cycle arrest with cGAS-STING activation. Upon glutathione triggered degradation, the nanoplatform releases the PLK1 inhibitor GSK461364 and Mn(2)(+) ions. Mechanistically, GSK461364 enforces G2/M arrest, profoundly amplifying radiation-induced DNA damage and immunogenic cell death. Crucially, this enriched cytosolic DNA pool is concurrently sensed by cGAS-STING pathway, which is vigorously sensitized by the Mn(2)(+) generated locally, culminating in robust type I interferon secretion. This synergistic modulation effectively remodels the immunosuppressive microenvironment, increases CD8(+) T cell infiltration and induces a strong abscopal effect against metastatic lesions. Collectively, combining cell cycle arrest with innate immune activation is a promising strategy to improve the efficacy of radio-immunotherapy.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.